A

patent appeals board has issued a ruling that may undermine a highly controversial tactic Allergan employed to avoid a contentious type of patent challenge.

In a decision Tuesday, the U.S. Patent Trial and Appeal Board ruled an entity cannot claim sovereign immunity in order to deflect inter partes reviews, or IPRs, if it is party to a patent infringement lawsuit in a federal court. The decision came in a case not related to Allergan, but holds the potential for derailing a carefully crafted move by the company to escape an IPR for patents on a huge-selling drug.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Excellent info. When would we know about ruling . Per stat plus team , how much are the chances for allergen to win the suit. Thank you

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.